Bioelectronics Corp (OTCMKTS:BIEL)’s ActiPatch Available on Amazon
Bioelectronics Corp (OTCMKTS:BIEL) the manufacturer of advanced pain management medical equipments reported that ActiPatch® is now available on the United States Amazon.com. ActiPatch is the major nonprescription pain treatment in the United Kingdom with more than 300 assessments that rate the device 4.5/5 on Walgreens/Boots site.
ActiPatch is for the more than 100 million chronic pain sufferers in the United States. The easy to wear medical device offers 720-hours of on/off treatment for $29.95. ActiPatch offers impressive efficacy, no adverse side effects, a 50% decline in medication use, counting opioids, exceptional consumer acceptance and demonstrated marketability. It is more of Safe adjunctive or alternative treatment to pain killers, comprising narcotics.
The Amazon site and the firm’s website have made available the firm’s award winning “Try & Tell” marketing product priced for $9.95. The 24/7 device introduces users to considerable long-lasting pain relief that permits a full night’s sleep and also restoration of daily activities deprived of any damaging side effects.
Chris Russell, the VP of Marketing at Bioelectronics, said that he anticipates the loud success that they have had in the U.K. to be mirrored in the U.S. They are steadily a top selling analgesic instrument for retailer firms like Amazon in the U.K. Now with U.S. FDA market approval, they expect similar success in the United States.
Bioelectronics is a pioneer in non-invasive electroceuticals and the manufacturer of an industry prominent family of throwaway, drug-free, pain treatment devices: ActiPatch®, over-the-counter cure for back pain and other musculoskeletal problems; RecoveryRx® Devices for post-operative and chronic wound care; and also Allay® Menstrual Pain treatment.
In the last trading session, the stock price of Bioelectronics gained over 22% to close the session at $0.00110. The gains came at a share volume of 357.90 million compared to average share volume of 145.05 million.© Copyright 2016 OTC News Magazine. All rights reserved.